Menu
2020 Session

Budget Amendments - SB30 (Member Request)

View Budget Item
View Budget Item amendments

Chief Patron: Edwards
340B Discriminatory Contracting Prohibited (language only)

Item 313 #3s

Item 313 #3s

Health and Human Resources
Department of Medical Assistance Services

Language

Page 321, after line 18, insert:

"GGGG.1.   A pharmacy benefit manager, or any other third party, that reimburses a 340B entity for drugs that are subject to an agreement under 42 U.S.C. §256b shall not reimburse the 340B entity for pharmacy-dispensed drugs at a rate lower than that paid for the same drug to pharmacies similar in prescription volume that are not 340B entities, and shall not request 3408 cost information, nor assess any fee, charge-back, or other adjustment upon the 340B entity on the basis that the 340B entity participates in the program set forth in 42 U.S.C. §256b.


2. With respect to a patient eligible to receive drugs subject to an agreement under 42 U.S.C. § 256b, a pharmacy benefit manager, or any other third party that makes payment for such drugs, shall not discriminate against a 3408 entity in a manner that prevents or interferes with the patient's choice to receive such drugs from the 3408 entity: Provided, that for purposes of this section, "third party" does not include the state Medicaid program when Medicaid is providing reimbursement for covered outpatient drugs, as that term is defined in 42 U.S.C. § 1396r-8(k), on a fee-for-service basis: Provided, however, that "third party" does include a Medicaid-managed care organization as described in 42 U.S.C. § 1396b(m).


3. This section does not apply with respect to claims under an employee benefit plan under the Employee Retirement Income Security Act of 1974 or, except for paragraph (d), to Medicare Part D."



Explanation

(This amendment provides that a pharmacy benefit manager, or any other third party, that reimburses a 340B entity for drugs that are subject to an agreement under 43 U.S.C. §256b shall not reimburse the 340B entity for pharmacy-dispensed drugs at a rate lower than that paid for the same drug to pharmacies similar in prescription volume that are not 340B entities, and shall not request 340B cost information, nor assess any fee, charge-back, or other adjustment upon the 340B entity on the basis that the 340B entity participates in the program set forth in 42 U.S.C. §256b.)